Novel Lavendamycin Analogues as Potent HIV-Reverse Transcriptase Inhibitors: Synthesis and Evaluation of Anti-Reverse Transcriptase Activity of Amide and Ester Analogues of Lavendamycin

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5773-5780

  Behforouz, Mohammad ^a   Cai, Wen ^a   Stocksdale, Mark G ^a   Lucas, Jennifer S ^a   Jung, Joo Yong ^a   Briere, Daniel ^a   Wang, Aiqin ^a   Katen, Kevin S ^a   Behforouz, Nancy C ^a  

^a BALL STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 N ACYLAMINO 2 FORMYLQUINOLINE 5,8 DIONE DERIVATIVE; ABACAVIR; AMIDE; AMINOQUINOLINE DERIVATIVE; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ESTER; INDINAVIR; LAMIVUDINE; LAVENDAMYCIN DERIVATIVE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RUFOCROMOMYCIN; SAQUINAVIR; STAVUDINE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; MOUSE; NONHUMAN; POLYMERIZATION;

AMIDES; ANIMALS; CELLS, CULTURED; DRUG SYNERGISM; ESTERS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICE; REVERSE TRANSCRIPTASE INHIBITORS; STREPTONIGRIN; STRUCTURE-ACTIVITY RELATIONSHIP; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0346366455     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0304414     Document Type: Article

References (29)

1. Piot, P.; Bartos, M.; Ghys, P. D.; Walker, N.; Schwartlander, B. The Global Impact of HIV/AIDS. Nature 2001, 410, 968-973.
2. Richman, D. D. HIV Chemotherapy. Nature. 2001, 410, 995-1001.
3. (b) Menendez-Arias, L. Targeting HIV: Antiretroviral Therapy and Development of Drug Resistance. Trends Pharmacol. Sci. 2002, 23, 381-388.
4. Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P.-F. BMS-232632, A Highly Potent Human Immunodeficiency Virus Protease Inhibitor that Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
5. (a) van Praag, R. M.; Wit, F. W.; Jurriaans, S.; de Wolf, F.; Prins, J. M.; Lange, J. M. Improved Long-Term Suppression of HIV-1 Replication with a Triple-Class Multidrug Regimen Compared with Standard of Care Antiretroviral Therapy. AIDS 2002, 16, 719-725.
6. (b) Havlir, D. V.; Lange, J. M. New Antiretrovirals and New Combinations. AIDS 1998, 12 suppl. A, s165-174.
7. (a) Campiani, G.; Ramunno, A. Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Nonnucleoside HIV Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
8. (b) Romero, D. L.; Busso, M.; Tan, C.-K.; Reusser, F.; Palmer, J. R.; Poppe, S. M.; Aristoff, P. A.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G. Non-Nucleoside Reverse Transcriptase Inhibtors That Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8806-8810.
9. (c) De Clerq, E. The Role of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Therapy of HIV-1 Infection. Antiviral Res. 1998, 38, 153-179.
10. Joly V.; Descamps, D.; Yeni, P. NNRTI Plus PI Combinations in the Perspective of Nucleoside-Sparing or Nucleoside-Failing Antiretroviral Regimens. AIDS Rev. 2002, 4, 128-139.
11. (a) Take, Y.; Kubo, T.; Takemori, E.; Inouye, Y.; Nakamura, S.; Nishimura, T.; Suzuki, H.; Yamaguchi, H. Biological Properties of Streptonigrin Derivatives III. In Vitro and In Vivo Antiviral and Antitumor Activities. J. Antibiot. 1989, 42, 968-976
12. (b) Balitz, D. M.; Bush, J. A.; Bradner, W. T.; Doyle, T. W.; O'Herron, F. A.; Nettleton, D. E. Isolation of Lavendamycin, a New Antibiotic from Streptomyces lavendulae. J. Antibiot. 1982, 35, 259-265.
13. Take, Y.; Inouye, Y.; Nakamura, S. Allaudeen, H. S.; Kubo, A. Comparative Studies of the Inhibitory Properties of Antibiotics on Human Immunodeficiency Virus and Avian Myeloblastosis Virus Reverse Transcriptases and Cellular DNA Polymerases. J. Antibiot. 1988, 42, 107-115.
14. (a) Boger, D. L.; Mitscher, Y. M.; Drake, S. D.; Kitos, P. A.; Thompson, S. C. Streptonigrin and Lavendamycin Partial Structures. Probes for the Minimum, Potent Pharmacophore of Streptonigrin, Lavendamycin, and Synthetic Quinoline-5,8-diones. J. Med. Chem. 1987, 30, 1918-1928.
15. (b) Kende, A. S.; Ebetino, F. H. The Regiospecific Total Synthesis of Lavendamycin Methyl Ester. Tetrahedron Lett. 1984, 25, 923-926.
16. (a) Behforouz, M.; Gu, Z.; Cai, W.; Horn, M. A.; Ahmadian, M. A Highly Concise Synthesis of Lavendamycin Methyl Ester. J Org. Chem. 1993, 58, 7089-7091.
17. (b) Behforouz, M.; Haddad, J.; Cai, W.; Arnold, M. B.; Mohammadi, F.; Sousa, A. C.; Horn, M. A. Highly Efficient and Practical Syntheses of Lavendamycin Methyl Ester and Related Novel Quinolinediones. J. Org. Chem. 1996, 61, 6552-6555.
18. Behforouz, M.; Zarrinmayeh, H.; Ogle, M. E.; Riehle, T. J.; Bell, F. W. β-Carbolines Derived from β-Methyltryptophan and a Stereoselective Synthesis of (2RS, 3SR)-β-Methyltryptophan Methyl Ester. J. Heterocycl. Chem. 1988, 25, 1627-1632.
19. Behforouz, M.; Haddad, J.; Cai, W.; Gu, Z. Chemistry of Quinoline-5,8-diones. J. Org. Chem. 1998, 63, 343-346.
20. Mitsunobu, O.; Kato, K.; Kimura, J. Selective Phosphorylation of 5-Hydroxy Groups of Thymidine and Uridine. J. Am. Chem. Soc. 1969, 91, 6510-6511.
21. Okada, H.; Mukai, H.; Inouye, Y.; Nakamura, S. Biological Properties of Streptonigrin Derivatives II. Inhibition of Reverse Transcriptase Activity. J. Antibiot. 1986, 39, 306-308.
22. (a) Coates, A. V.; Cammack, N.; Jenkinson, H. J.; Jowett, A. J.; Jowett, M. I.; Pearson, B. A.; Penn, C. R.; Rouse, P. L.; Viner, K. C.; Cameron, J. M. (-)-2′-Deoxy-3′-Thiacytidine Is A Potent, Highly Selective Inhibitor of Human Immunodeficiency Virus Type 1 and Type 2 Replication In Vitro. Antimicrob. Agents Chemother. 1992, 36, 733-739.
23. (b) Bilello, J.; Bauer, G.; Dudley, M. Effect of 2′-3′ -dihydro-3′-deoxythymidine in an In Vitro Hollow Fiber Pharmacodynamic Model System Correlates with Results of Dose-Ranging Clinical Studies. Antimicrob. Agents Chemother. 1994, 38, 1386-1391.
24. (a) Reilly, H. C.; Sugiura, K. An Antitumor Spectrum of Stretonigrin. Antibiot. Chemother. 1961, 11, 174-177.
25. (b) Olesen, J. J.; Calderella, L. A.; Mjos, K. J.; Reith, A. R.; Thie, R. S.; Toplin, I. Effects of Streptonigrin on Experimental Tumors. Antibiot. Chemother. 1961, 11, 158-164.
26. Kim, J. Y.; Su, T.-L.; Chou, T.-C.; Koehler, B.; Scarborough, A.; Ouerfelli, O.; Watanabe, K. A. Cyclopent[a] anthraquinones as DNA -Intercalating Agents with Covalent Bond Formation Potential; Synthesis and Biological Activity. J. Med. Chem. 1996, 39, 2812-2818
27. Casazza, A. M.; Savi, G.; Pratesi, G.; Di Marco, A. Antitumor Activity in Mice of 4′- Deoxydoxorubicin in Comparison with Doxorubicin. Eur J. Cancer Clin. Oncol. 1983, 19, 411-418.
28. (a) Chou, T. C.; Talalay, P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
29. (b) Chou J.; Chou, T. C. Dose BEffect Analysis with Microcomputers: Quantitation of ED50, LD50, Synergism, Antagonism, Low-Dose Risk, Receptor-Ligand Binding and Enzyme Kinetics. In: A computer Software for IBM-PC and Manual. Cambridge, UK: Elsevier-Biosoft, 1987.